Pharma channel feed

Agios lines up sol­id PhI­II da­ta to back Tib­sovo's use in bile duct can­cer — ahead of planned sN­DA

6 years ago
R&D

FDA clears short­er treat­ment reg­i­men for Ab­b­Vie's hep C treat­ment, Mavyret. Will pa­tients ben­e­fit?

6 years ago
R&D
FDA+

Mer­ck­'s top can­cer team basks in the warm light of pos­i­tive Keytru­da da­ta from a land­mark study for hard-to-treat breast can­cer

6 years ago
R&D

No­var­tis, Eli Lil­ly mar­quee pos­i­tive sur­vival da­ta for CDK 4/6 fran­chis­es — but can they ac­tu­al­ly beat Pfiz­er's block­buster?

6 years ago
R&D

Bank­ing on Op­di­vo/Yer­voy com­bo, Bris­tol-My­ers Squibb teas­es out Check­mate-227 again at ES­MO

6 years ago
R&D

As­traZeneca her­alds Tagris­so's OS lead over old TKIs in lung can­cer niche

6 years ago
R&D

PRI­MA vs PAO­LA: GSK and Mer­ck/As­traZeneca square off in a high-pro­file PARP show­down at ES­MO

6 years ago
R&D

Bris­tol-My­ers Squib­b's Op­di­vo could­n't top­ple Nex­avar in HCC — but will bet­ter safe­ty pro­file win over physi­cians?

6 years ago
R&D

Pfiz­er's JAK in­hibitor clears sec­ond piv­otal eczema study, but can it top­ple Re­gen­eron's Dupix­ent?

6 years ago
R&D

Darza­lex from J&J, Gen­mab scores FDA ap­proval in front­line mul­ti­ple myelo­ma use as Sanofi ri­val looms

6 years ago
R&D

Deep im­pact: Drugs to watch in Q3 — PBM analy­sis

6 years ago
R&D

GSK in­fus­es $120M in­to next-gen man­u­fac­tur­ing fa­cil­i­ties at Up­per Meri­on, PA

6 years ago

Re­pub­li­cans re­buke Pelosi drug pric­ing bill

6 years ago
FDA+

Top GSK/Vi­iV sci­en­tist who co-in­vent­ed an HIV block­buster books a trip to biotech

6 years ago
People
R&D

'Worse than ever,' Boston's biotechs stare down traf­fic cri­sis — prompt­ing call for more re­mote work­ing, flex hours

6 years ago

No­var­tis ac­cus­es 2 AveX­is founders of al­ter­ing da­ta, stonewalling probe — but ex-CSO blasts back

6 years ago
Cell/Gene Tx
FDA+

Servi­er be­gins manslaugh­ter tri­al over weight loss drug

6 years ago

Here comes the oral GLP-1 drug for di­a­betes — and No­vo Nordisk wants to price Ry­bel­sus 'at a sim­i­lar lev­el as Ozem­pic'

6 years ago
R&D

Astel­las' AML drug wins over CHMP — strength­en­ing lead on Dai­ichi Sankyo

6 years ago

Pur­due threat­ens to walk away from set­tle­ment, asks to pay em­ploy­ees mil­lions in bonus­es

6 years ago

Genen­tech sub­mits a big plan to ex­pand its South San Fran­cis­co foot­print

6 years ago
R&D

Em­maus re­scinds EU mar­ket­ing ap­pli­ca­tion, fol­low­ing neg­a­tive re­view

6 years ago
FDA+

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

6 years ago
R&D

Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

6 years ago
People
First page Previous page 265266267268269270271 Next page Last page
A service from the Financial Times